 Drug maker Hospira Inc took the unusual step of filing a lawsuit to challenge the US Food and Drug Administrations approval this week of generic copies of the companys bestselling product the sedative Precedex Hospira is trying to preserve its market exclusivity for Precedex which accounts for about  of the companys  billion of annual sales The drug is approved to sedate intubated patients in an intensivecare setting as well as nonintubated patients before and during surgeries and other procedures